GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Institutional Ownership

NaviFUS (ROCO:6872) Institutional Ownership : 0.00% (As of Jun. 20, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NaviFUS's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NaviFUS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NaviFUS's Float Percentage Of Total Shares Outstanding is 0.00%.


NaviFUS Institutional Ownership Historical Data

The historical data trend for NaviFUS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Institutional Ownership Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Institutional Ownership
Get a 7-Day Free Trial - - - - -

NaviFUS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Institutional Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NaviFUS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


NaviFUS (ROCO:6872) Business Description

Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines